33-9400

antibody from Invitrogen Antibodies

Targeting: SRSF3 SFRS3, SRp20

Provider product page for 33-9400

Western blot

ELISA

Other assay

Antibody data

Antibody Data
Antigen structure
References [13]
Comments [0]
Validations
Other assay [8]

Submit

Product number: 33-9400 - Provider product page
Provider: Invitrogen Antibodies
Product name: SRSF3 Monoclonal Antibody (1H4G7)
Antibody type: Monoclonal
Antigen: Other
Reactivity: Human, Xenopus
Host: Mouse
Isotype: IgG
Antibody clone number: 1H4G7
Vial size: 100 µg
Concentration: 0.5 mg/mL
Storage: -20°C

SRSF3 protein structure - 33-9400 shown in red.

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: NULL

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: NULL

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: NULL

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: NULL

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: NULL

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Figure 6 Digoxin alters the activity of SR protein kinases and induces modification of a subset of SR proteins. (A) To assess the effect of digoxin on CLK kinase function, HeLa rtTA-HIV-Delta Mls cells were transfected with vectors expressing GFP-tagged CLK1. Twenty-four hours post-transfection, cells were treated with DMSO or 100 nM digoxin. After 24 h of treatment, cells were fixed, stained for SC35/SRSF2 nuclear speckles (Texas Red), and nuclei stained with DAPI. Images are representative of the localization patterns observed from >=5 independent experiments. Magnification 630x. (B, C, D) Western blot analysis of the effect of digoxin treatment on SR proteins. Lysates were harvested from HeLa rtTA-HIV-Delta Mls cells treated with 100 nM digoxin or DMSO and were induced with Dox (+) or left uninduced (-) as described in Fig. 1 . Immunoblots were probed by specific antibody for (B) phospho-SR proteins (1H4) or (C) SRp20, Tra2beta1, 9G8, or SF2/ASF (SF2). (D) Cell lysates from above were dephosphorylated by treatment with (+) and without (-) calf intestinal alkaline phosphatase (CIP), then immunoblotted with a SRp20-specific antibody. Arrows on the right indicate the protein specie(s) detected and their modified/unmodified isoform(s). Anti-tubulin (Anti-Tub.) blots for each experiment served as an internal loading control for the relative amount of protein lysate per lane. Immunoblots are representative of >=4 independent trials.

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Figure 2 miR-183 regulates the splicing factor SC35. a QRT-PCR for miR-183 in CHO cells transfected with pre-miR-183 or anti-miR-183 (Ambion) and GFP-transfected controls. Bars : SD; t test p < 10 -5 for both concentrations of pre-miR-183 compared to GFP control. b Scan and quantification of immunoblot for SC35 in cells in a with alpha-tubulin used for normalization. c Suggested interplay of alternative splicing and miRs (exemplified by miR-134, miR-183, and their target, the splicing factor SC35) contributes to the complexity of stress responses in the brain, including regulation of the alternative splicing choice between the major ""synaptic"" AChE transcript AChE-S and the normally minor stress-induced variant AChE-R

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Figure 7 Overexpression of SRp20, Tra2beta1, or Tra2beta3 suppress HIV-1 expression. (A) Diagram of SRp20, Tra2beta1, and Tra2beta3 protein domain structure. (B) Cells were transfected with the vectors CMVmyc (mock), CMVmyc SRp20 (SRp20), CMVmyc Tra2beta1 (Tra2beta1), or CMVmyc Tra2beta3 (Tra2beta3). Forty-eight hours post-transfection, cells were harvested, lysed in RIPA buffer, and proteins analyzed by western blot with anti-myc antibody followed by anti-tubulin (Tubulin) antibody to indicate loading. (C) HeLa rtTA-HIV-Delta Mls cells were transfected with (+) (or without, -) CMVtTApA (tTA) to activate the endogenous HIV-1 provirus along with CMV PLAP and either CMVmyc, CMVmyc SRp20, CMVmyc Tra2beta1, or CMVmyc Tra2beta3. Forty-eight hours post transfection, cell media was harvested and assayed by p24 CA ELISA for expression of HIV-1 Gag (black) and production of SEAP (white). Results are averaged from 6 independent assays, error bars are SEM, and asterisks indicate values deemed significant from CMVmyc (+tTA) as detailed in "" Materials & Methods "". (D) In parallel, total RNA was extracted from transfected cells and the abundance of individual viral RNA (unspliced, US; singly spliced, SS; multiply spliced, MS) were determined by qRT-PCR. Shown are results averaged from 6 independent assays, error bars are SEM, and asterisks indicate significance as noted above. (E, F) MS HIV-1 RNAs from transfected cells were amplified by RT-PCR as described in Fig. 4 . Amplicons were fra